title: [Malignant lymphoma in the central nervous system: overview].
abstract: Malignant lymphoma can affect the central nervous system (CNS) in three different ways: as a consequence (relapse or invasion) of systemic lymphoma, as a primary CNS lymphoma (PCNSL) without systemic involvement, and through intravascular lymphomatosis (IVL). It is essential to distinguish PCNSL from the others, since the therapeutic strategy for treating this disease differs. FDG-PET/CT fusion imagery is a powerful tool for detecting systemic lesions. If a marked elevation of lactate dehydrogenase and the soluble IL-2 receptor suggests IVL, a random skin biopsy can permit a differential diagnosis. It is not certain why PCNSL occurs solely in the CNS, where there is no lymphatic system. The special environment, so-called "sanctuary site", where is free from attack of the immune system and penetration of chemotherapeutic agents by blood-brain barrier is deeply related to malignant transformation. The prognoses for patients with CNS invasion of systemic lymphoma and those with PCNSL remain bleak in the post-rituximab era. Over half of the patients who received high-dose methotrexate will subsequently relapse. Therefore, novel therapeutic strategies are earnestly sought.
authors.affiliation: Department of Neurology, Jichi Medical University School of Medicine.
authors.forename: Michito
authors.initials: M
authors.lastname: Namekawa
mesh_terms: D001812:Blood-Brain Barrier / Q000473:pathology; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis / Q000188:drug therapy*; D008727:Methotrexate / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy*; D049268:Positron-Emission Tomography / Q000379:methods
chemical_list: D008727:Methotrexate